Human Immunodeficiency Virus Type 1 Vectors with Alphavirus Envelope Glycoproteins Produced from Stable Packaging Cells

Strang, Blair L.; Takeuchi, Yasuhiro; Relander, Thomas; Richter, Johan; Bailey, R. H.; Sanders, D.A.R.; Collins, Mary; Ikeda, Yasuhiro

doi:10.1128/jvi.79.3.1765-1771.2005

Cited by 36 publications

(41 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although numerous groups reported attempts to generate stable, well-characterized packaging cell lines, [64][65][66][67][68][69] none of these systems are currently widely used, probably because the overall benefit compared to transient transfection remains relatively modest. The major problem with the development of such cell lines is the cytotoxicity of constitutive expression of high amounts of HIV-1 proteins, such as pol, gag, vpr, tat, rev and protease.…”

Section: Downstream Processing Of Lentiviral Vectorsmentioning

confidence: 99%

“…41 Engineering inducible expression under the control of a drug-dependent element of both the viral proteins and VSV.G has resulted in stable packaging cell lines, resulting in acceptable vector yield, varying between 10 5 and 10 7 TU/ml. [64][65][66][67] Alternatively, replacing VSV.G with glycoproteins displaying an equally broad tropism but that do not lead to producer cell death, such as baculovirus envelope, 74 gammavirus envelope 68 or alphavirus envelope, 69 has enabled the establishment of stable packaging cell lines. However, it is obvious that only virus production with stable packaging cell lines can meet the demands for clinical use when it comes to reproducibility and standardization.…”

Section: Downstream Processing Of Lentiviral Vectorsmentioning

confidence: 99%

See 1 more Smart Citation

Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics

2007

View full text Add to dashboard Cite

Lentiviral vectors have emerged as promising tools for both gene therapy and immunotherapy purposes. They exhibit several advantages over other viral systems in that they are less immunogenic and are capable of transducing a wide range of different cell types, including dendritic cells (DC). DC transduced ex vivo with a whole range of different (tumor) antigens were capable of inducing strong antigen-specific T-cell responses, both in vitro and in vivo. Recently, the administration of lentiviral vectors in vivo has gained substantial interest as an alternative method for antigenspecific immunization. This method offers a number of advantages over DC vaccines as the same lentivirus can in principle be used for all patients resulting in a significantly reduced cost and requirement for considerably less expertise for the generation and administration of lentiviral vaccines. By selectively targeting lentiviral vectors to, or restricting transgene expression in certain cell types, selectivity, safety and efficacy can be further improved. This review will focus on the use of direct administration of lentiviral vectors encoding tumor-associated antigens (TAA) for the induction of tumor-specific immune responses in vivo, with a special focus on problems related to the generation of large amounts of highly purified virus and specific targeting of antigenpresenting cells (APC).

show abstract

Section: Downstream Processing Of Lentiviral Vectorsmentioning

confidence: 99%

Section: Downstream Processing Of Lentiviral Vectorsmentioning

confidence: 99%

Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics

2007

View full text Add to dashboard Cite

show abstract

“…7 Recombinant lentiviral particle production is obtained by transiently expressing the viral structural components along with the transfer vector 1 or, to a lesser degree, by the use of stable vector-producing cell lines. [8][9][10][11] For clinical application, vectors produced by stable cell lines could be preferred over the transiently generated ones, as in-depth molecular characterization of the producer line ensures a continuous source of vector particles and their extensive quality control, reducing therefore batchto-batch variation and allowing higher level of safety. Indeed, several stable packaging cell lines have been generated.…”

Section: Introductionmentioning

confidence: 99%

“…Indeed, several stable packaging cell lines have been generated. [9][10][11] However, this approach is laborious and time-consuming, and the toxicity of lentiviral (enzymes and accessory) proteins as well as the fusogenicity of the rhabdovirus vesicular stomatitis virus G protein (VSV-G), most commonly used to pseudotype HIV-1 vector particles, requires tight control of gene(s) expression, 11 complicating constitutive production of recombinant virions. The first clinical trial by means of an HIV-1-based vector has indeed been pursued by scaling up transiently produced lentiviral particles.…”

Section: Introductionmentioning

confidence: 99%

Analysis of human immunodeficiency virus type 1 vector cis- and trans-acting elements production by means of Semliki Forest virus

et al. 2008

View full text Add to dashboard Cite

“…Another approach to obtain a largescale production has been to replace the toxic VSV-G protein with a less-toxic glycoprotein. A variety of different envelope glycoproteins like those from gammaretroviruses (for example, feline endogenous retrovirus RD114 env, modified gibbon-ape leukemia virus, moloney murine leukemia virus) alphaviruses, lyssaviruses or baculoviruses were shown to pseudotype lentiviral vectors [14][15][16][17] Pseudotyping broadens the transduction range and can strengthen the otherwise fragile lentivirus (reviewed in Cronin et al…”

Section: Introductionmentioning

confidence: 99%

Generation of lentivirus vectors using recombinant baculoviruses

et al. 2008

View full text Add to dashboard Cite

In spite of advances in conventional four-plasmid transient transfection methods and development of inducible stable production cell lines, production of replication-defective lentiviral vectors in clinical scale has been challenging. Baculovirus technology offers an alternative to scalable virus production as a result of fast and easy production of baculoviruses, efficient transduction of mammalian cells and safety of the baculoviruses. As a first step toward scalable lentiviral production system, we have constructed four recombinant baculoviruses: the BAC-transfer virus expresses green fluorescent protein (GFP) as a transgene and BAC-gag-pol, BAC-vesicular stomatitis virus glycoprotein G and BAC-rev express all elements required for a safe lentivirus vector generation. Following 293T cell transduction with recombinant baculoviruses functional lentiviruses were produced. Different baculovirus concentrations, mediums and transduction times were used to find optimal conditions for lentivirus production. The unconcentrated lentiviral titers in cell culture mediums were on average 2.5 Â 10 6 TU ml À1 , which are comparable to titers of the lentiviruses produced by conventional four-plasmid methods. Lentiviruses produced by baculovirus method transduced HeLa cells and showed sustained GFP expression. No evidence of the formation of replication competent lentiviruses was detected by p24 enzyme-linked immunosorbent assay. Our results show that baculoviruses are an attractive alternative for the production of lentiviruses in mammalian cells.

show abstract

Human Immunodeficiency Virus Type 1 Vectors with Alphavirus Envelope Glycoproteins Produced from Stable Packaging Cells

Cited by 36 publications

References 37 publications

Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics

Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics

Analysis of human immunodeficiency virus type 1 vector cis- and trans-acting elements production by means of Semliki Forest virus

Generation of lentivirus vectors using recombinant baculoviruses

Contact Info

Product

Resources

About